In this review article, we provide an overview of FAK expression and activity in the context of tumour biology, and we discuss the current evidence of the role of this protein in HCC development and progression, suggesting its potential use as a therapeutic target. This evidence concerns the gene PTK2 and hepatocellular carcinoma.